Metabolic

Cagrilintide

A long-acting amylin analog studied for appetite and weight, often with semaglutide.

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog that influences appetite and satiety. It has been studied both on its own and in combination with semaglutide (as CagriSema) for weight management.

Also known as: Cagri, AM833

Read the in-depth Cagrilintide guide

How Cagrilintide is studied

Cagrilintide is a long-acting analog of amylin, a hormone co-released with insulin that promotes satiety and slows gastric emptying. It is studied on its own and combined with semaglutide (as CagriSema) for appetite and weight management.

Commonly researched for

Appetite regulationWeight managementSatiety

Typically stacked with

Semaglutide

Research status

Clinical trials — investigational.

Important considerations

Investigational and not approved as a standalone product. Medical supervision advised.

View published research on PubMed

Cagrilintide — frequently asked questions

Appetite regulation and weight management, both alone and in combination with semaglutide. It is investigational.

Amylin is a hormone released with insulin that promotes fullness; a long-acting analog like cagrilintide extends that satiety effect.

No. It is investigational and studied in clinical trials, not approved as a standalone product.

This page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.